Advances in the study of antibody-coupled drugs in the treatment of small cell lung cancer
GUO Mengya
LIU Ying
CAI Ruoxue
CHEN Yue
HU Shuyi
FANG Ying
ZHOU Guoren
Abstract：Small cell lung cancer(SCLC)has high malignant degree,high recurrence rate,early metastasis,and poor prognosis.For SCLC patients,the standard treatment is radiotherapy combined with chemotherapy,and the treatment strategies are limited.Antibody-drug conjugates(ADCs)are novel drugs consisting of antibodies,carriers and linkers,which perfectly combine the killing effect of chemotherapy and the precision of targeted therapy.ADCs have been widely used in the treatment of breast cancer,and the related research in the treatment of SCLC is also booming,mainly involving delta-like ligand 3(DLL-3),cluster of differentiation 56(CD56),trophoblast cell-surface antigen 2(TROP-2)and B7 homologue 3(B7-H3).In recent years,ADCs have also achieved preliminary efficacy in the treatment of SCLC,showing good anti-tumor activity,which is expected to provide a new therapeutic option for SCLC patients.
Keywords：Antibody-coupled drugLung cancerSmall cell lung cancerTargetingResearch progress
Publication Date：2024-08-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 405-410 )